share_log

Oppenheimer Maintains Outperform on Evaxion Biotech, Lowers Price Target to $11

Oppenheimer Maintains Outperform on Evaxion Biotech, Lowers Price Target to $11

奥本海默保持对Evaxion Biotech的优异表现,将目标价下调至11美元
Benzinga Real-time News ·  2022/11/17 08:36

Oppenheimer analyst Jeff Jones maintains Evaxion Biotech (NASDAQ:EVAX) with a Outperform and lowers the price target from $16 to $11.

奥本海默分析师Jeff·琼斯维持纳斯达克(EVAX)的强于大盘表现,并将目标价从16美元下调至11美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发